Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months). Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years. Multivariate analysis revealed that the presence of secondary chromosome aberrations in addition to t(9;22) at diagnosis constitute an independent predictive value for RFS (p=0.027), and increase the risk of treatment failure by 2.8-fold.
Yanada
Masamitsu
M
Nagoya University Graduate School of Medicine, Nagoya, Japan. myanada@mdanderson.org
Takeuchi
Jin
J
Sugiura
Isamu
I
Akiyama
Hideki
H
Usui
Noriko
N
Yagasaki
Fumiharu
F
Nishii
Kazuhiro
K
Ueda
Yasunori
Y
Takeuchi
Makoto
M
Miyawaki
Shuichi
S
Maruta
Atsuo
A
Narimatsu
Hiroto
H
Miyazaki
Yasushi
Y
Ohtake
Shigeki
S
Jinnai
Itsuro
I
Matsuo
Keitaro
K
Naoe
Tomoki
T
Ohno
Ryuzo
R
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000008:administration & dosage*; D012008:Recurrence; D015996:Survival Rate; D014184:Transplantation, Homologous
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate